Meeting
2022 ASCO Annual Meeting
KEYNOTE B68: Open-label phase 2 study of the efficacy and safety of pembrolizumab administered every six weeks in patients with relapsed or refractory classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma.
Authors
Philippe Armand
Dana-Farber Cancer Institute, Boston, MA
Philippe Armand , Kumudu Pathiraja , Samhita Chakraborty , Patricia Marinello
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Hodgkin Lymphoma
Clinical Trial Registration Number
NCT04875195
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS7585)
DOI
10.1200/JCO.2022.40.16_suppl.TPS7585
Abstract #
TPS7585
Poster Bd #
234a
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-naïve patients with advanced non–small cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of a randomized, open-label, multicenter, phase 2 study.
First Author: Tony S. K. Mok
Poster
2017 ASCO Annual Meeting
Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: Interim results of an on open-label, phase II study.
First Author: Loretta J. Nastoupil
Poster
2016 ASCO Annual Meeting
Phase 2 study of the safety and efficacy of pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for advanced melanoma (KEYNOTE-022).
First Author: Georgina V. Long
Poster
2014 ASCO Annual Meeting
A phase I/II study to assess the safety and efficacy of pazopanib and MK-3475 in subjects with advanced renal cell carcinoma.
First Author: David F. McDermott